The Janssen Pharmaceutical Companies of Johnson & Johnson announced on August 10th 2021 that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Marketing Authorisation in Great Britain for PONVORY® (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.2-4 “We are delighted…
Istradefylline: CHMP issues negative opinion for in Europe
On 23rd July, Kyowa Kirin Co., Ltd. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people…
Bial and Medis partnership
13 July 2021: BIAL and Medis, d.o.o. have entered into an exclusive partnership on two of BIAL’s proprietary drugs: Zebinix® (eslicarbazepine acetate) and Ongentys® (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix® (eslicarbazepine acetate) in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys® (opicapone) in 12 CEE countries…
STARS recognises healthcare professionals working to reduce misdiagnosis and sudden cardiac death
In a new report published on 14th July 2021, STARS Healthcare Pioneers Report Showcasing Best Practice in Syncope 2021, the charity STARS highlights the innovative and inspiring work that is being done to improve care and quality of life for people experiencing an unexplained loss of consciousness (including syncope; aka fainting). People with syncope/fainting are…
The British Society of Pharmacy Sleep Services launched
12th July 2021 saw the launch of the British Society of Pharmacy Sleep Services (BSPSS) bspss.org The Society will support through education, community pharmacists’ knowledge and understanding of various sleep disorders, to ensure that patients receive timely and appropriate advice and are signposted to other healthcare professionals where necessary. The BSPSS is undertaking research bspss.org…
Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis in Scotland
The Scottish Medicines Consortium recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS) On July 12th 2021, Novartis announced that eligible patients in Scotland will soon have access to Kesimpta® (ofatumumab), the first self-administered, targeted B-cell therapy for patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical…
Pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS. Prilenia recently received a positive opinion from the Committee of Orphan Medicinal Products (COMP) in…
Organization for Human Brain Mapping: BrainArt
The Organization for Human Brain Mapping (OHBM) is an international society dedicated to fostering our understanding of brain organisation and function using neuroimaging techniques. Within the Society, various Special Interest Groups (SIGs) are dedicated to the promotion of shared interests, such as open science or trainees education. The annual OHBM competition highlights an ongoing aim…
William Wordsworth’s former Lake District home transformed into neurorehabilitation centre
Calvert Reconnections has today opened its doors – transforming the one-time Lake District home of poet William Wordsworth into a neurorehabilitation centre. It is located at Old Windebrowe, a Grade II listed Tithe barn on the outskirts of the bustling market town of Keswick in the Lake District. The centre is the UK’s first residential…
